Close

BCRX Financial Facts

Basic and diluted net loss per common share: -0.16
Royalties: 3.5M
See Full Income Statement

Marketable securities: 17.43M
Inventories: 2.23M
See Full Balance Sheet

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings

  |   Expand Research on BCRX
Next EPS Date 5/2/24 EPS Growth Rate +28.6%
Average EPS % Beat Rate +3.6% Revenue Growth Rate +26.6%
Average % Move 1-Wk after EPS +2.7% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/2/24 Q124 N/A-$0.20 N/A N/A$86.62M N/A N/A N/A
2/26/24 Q423 -$0.28-$0.25 -$0.03$93.4M$89.97M N/A Details
11/2/23 Q323 -$0.19-$0.25 +$0.06$86.74M$86.06M N/A Details
8/3/23 Q223 -$0.24-$0.23 -$0.01$81M$81.41M N/A Details
5/3/23 Q123 -$0.28-$0.30 +$0.02$68.4M$71.47M N/A Details
2/21/23 Q422 -$0.38-$0.17 -$0.21$79.5M$75.57M N/A Details
11/1/22 Q322 -$0.33-$0.29 -$0.04$40.99M$74.62M N/A Details
8/4/22 Q222 -$0.32-$0.34 +$0.02$65.2M$63.33M N/A Details